查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1842328

全球生物相似契约製造市场：市场规模、份额和趋势分析（按供应来源、治疗领域、服务和地区划分），细分市场预测（2025-2033 年）

Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Therapeutic Area (Oncology, Blood Disorders), By Service, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

生物相似契约製造：市场概览

全球生物相似契约製造市场预计在 2024 年达到 78.4 亿美元，预计到 2033 年将达到 251.9 亿美元，2025 年至 2033 年的复合年增长率为 13.87%。

癌症、糖尿病和自体免疫疾病等慢性疾病的日益普遍，推动了对价格合理的生技药品的需求。

生物相似药为昂贵的品牌生技药品提供了经济有效的替代方案，因此非常适合医疗保健系统和患者。製药公司越来越多地将生物相似药的生产外包给受託製造厂商(CMO)，以降低营运成本、确保符合监管要求并加快产品上市速度。这种不断增长的需求，加上重磅生技药品专利到期，显着扩大了受託製造服务的市场，使药物研发人员能够专注于创新，同时利用 CMO 在大规模、高效能生物相似药生产方面的专业知识。

此外，单株抗体、胰岛素类似物和生长因子等重磅生技药品的专利到期，为生物相似药生产商创造了巨大的机会。由于生技药品市场涉及数十亿美元的收入，製药公司竞相开发生物相似药以抢占市场份额。然而，由于生物製剂生产流程极为复杂，许多公司开始转向拥有生技药品开发、规模化生产和法规遵从专业知识的受託製造厂商（CMO）。这一趋势正在加速外包伙伴关係，从而加快生物相似药的上市速度，同时降低风险和营运成本，刺激市场成长。

此外，为了满足日益增长的生物相似药需求，契约製造）正积极投资于先进的生物製造技术，例如一次性系统、大容量生物反应器和连续生产流程。这些技术进步提高了效率、灵活性和扩充性，吸引製药公司与CMO合作。同时，CMO也在扩大其全球设施，以符合当地监管标准并支持跨国药物上市。此类扩建使生物相似药开发商能够克服基础设施限制、降低初始投资成本并加速商业化进程。 CMO日益精湛的技术和全球化的业务布局使其成为不可或缺的合作伙伴，从​​而推动了市场成长。

此外，美国、欧洲和新兴经济体等主要市场法规环境的改善正在促进生物相似药的推广应用。美国FDA和EMA等监管机构已建立简化的核准途径，在确保安全性和有效性的同时，也加快了产品进入市场的速度。这个框架鼓励了对生物相似药研发的投资，并推动了对高品质生产合作伙伴的需求。受託製造厂商）拥有遵守严格监管标准的专业知识，并透过为企业提供合规保证和全球市场进入获益。随着全球监管环境的日益明朗，预计企业对CMO在生物相似药生产方面的依赖程度将会增加，从而进一步推动市场成长。

目录

第一章 分析方法和范围

第二章执行摘要

第三章：生物相似药契约製造市场：驱动因素、趋势与范围

  • 市场联动展望
    • 附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 经营模式分析
  • 产品平臺分析
  • 服务定价模式分析
  • 技术进步
  • 供应链分析
  • 生物相似契约製造市场：分析工具
    • 波特五力分析
    • PESTEL分析与SWOT分析

第四章：生物相似契约製造市场：依供应来源分類的估算与趋势分析

  • 细分仪表板
  • 生物相似契约製造市场：按供应来源分類的差异分析
  • 依供应来源划分（2021-2033 年）
  • 哺乳动物
  • 非哺乳动物

第五章：生物相似契约製造市场：按服务类型分類的估算与趋势分析

  • 细分仪表板
  • 生物相似契约製造市场：按服务类型分類的差异分析
  • 依服务年资（2021-2033）
  • 重组非糖基化蛋白
  • 重组糖基化蛋白

第六章：生物相似契约製造市场：依治疗领域分類的估算与趋势分析

  • 细分仪表板
  • 生物相似契约製造市场：按治疗领域分類的差异分析
  • 依治疗领域划分（2021-2033 年）
  • 肿瘤学
  • 血液疾病
  • 生长激素缺乏症
  • 慢性病与自体免疫疾病
  • 类风湿性关节炎
  • 其他的

第七章：生物相似契约製造市场：区域估算与趋势分析

  • 区域展望
  • 生物相似契约製造市场：波动分析（按地区划分）
  • 按地区划分（2021-2033 年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特
    • 阿曼
    • 卡达

第八章 竞争情势

  • 公司分类
    • 市场领导
    • 新兴企业
  • 2024年企业市场估值分析（企业热力图分析）
  • 主要企业简介
    • Boehringer Ingelheim GmbH
    • Lonza
    • Rentschler Biopharma SE
    • AGC Biologics
    • ProBioGen
    • FUJIFILM Diosynth Biotechnologies
    • Toyobo Co. Ltd.
    • Samsung Biologics
    • Thermo Fisher Scientific, Inc.
    • Binex Co., Ltd.
    • WuXi Biologics
    • AbbVie, Inc.
    • ADMA Biologics, Inc.
    • Catalent, Inc
    • Cambrex Corporation
    • Pfizer Inc.
    • Siegfried Holding AG
Product Code: GVR-4-68039-970-1

Biosimilar Contract Manufacturing Market Summary

The global biosimilar contract manufacturing market size was estimated at USD 7.84 billion in 2024 and is projected to reach USD 25.19 billion by 2033, growing at a CAGR of 13.87% from 2025 to 2033. The increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is driving demand for affordable biologics.

Biosimilars offer cost-effective alternatives to expensive branded biologics, making them highly suitable for healthcare systems and patients. Pharmaceutical companies are increasingly outsourcing biosimilar production to contract manufacturing organizations (CMOs) to reduce operational costs, ensure regulatory compliance, and accelerate time-to-market. This growing demand and patent expirations of blockbuster biologics fuel strong market expansion for contract manufacturing services, enabling drug developers to focus on innovation while leveraging CMOs' expertise in large-scale, efficient biosimilar production.

In addition, expiration of patents for blockbuster biologics such as monoclonal antibodies, insulin analogs, and growth factors has opened significant opportunities for biosimilar manufacturers. With billions of dollars in biologics revenue at stake, pharmaceutical companies are increasingly racing to develop biosimilars to capture market share. However, due to high production complexity, many companies rely on contract manufacturing organizations (CMOs) with specialized expertise in biologics development, scale-up, and regulatory compliance. This trend accelerates outsourcing partnerships, enabling faster biosimilar launches while reducing risks and operational costs, thereby driving market growth.

Furthermore, contract manufacturing organizations are heavily investing in advanced biomanufacturing technologies, including single-use systems, high-capacity bioreactors, and continuous processing, to meet the rising demand for biosimilars. These technological advancements enhance efficiency, flexibility, and scalability, attracting pharmaceutical companies to partner with CMOs. In addition, CMOs are expanding global facilities to comply with regional regulatory standards, supporting multinational drug launches. Such expansions enable biosimilar developers to overcome infrastructure limitations, reduce upfront investment costs, and accelerate commercialization timelines. The increasing sophistication and global footprint of CMOs make them indispensable partners, propelling market growth.

Besides these, supportive regulatory environments in key markets such as the U.S., Europe, and emerging economies are fostering the adoption of biosimilars. Regulatory agencies such as the U.S. FDA and EMA have established streamlined approval pathways, ensuring safety and efficacy while expediting market entry. These frameworks encourage investment in biosimilar development, driving demand for high-quality manufacturing partners. Contract manufacturing organizations benefit from their expertise in adhering to stringent regulatory standards, providing companies with compliance assurance and global market access. As regulatory clarity improves worldwide, the reliance on CMOs for biosimilar production is expected to intensify, boosting market growth further.

Global Biosimilar Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biosimilar contract manufacturing market report based on source, service, therapeutic area, and region

  • Source Outlook (Revenue, USD Million, 2021 - 2033)
  • Mammalian
  • Non-mammalian
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Recombinant Non-glycosylated Proteins
  • Recombinant Glycosylated Proteins
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic & Autoimmune Disorders
  • Rheumatoid Arthritis
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Biosimilar Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Model Analysis
  • 3.4. Product Pipeline Analysis
  • 3.5. Service Pricing Model Analysis
  • 3.6. Technological Advancements
  • 3.7. Supply Chain Analysis
  • 3.8. Biosimilar Contract Manufacturing Market Analysis Tools
    • 3.8.1. Porter's Five Forces Analysis
    • 3.8.2. PESTEL by SWOT Analysis

Chapter 4. Biosimilar Contract Manufacturing Market: Source Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Biosimilar Contract Manufacturing Market: Source Movement Analysis
  • 4.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • 4.4. Mammalian
    • 4.4.1. Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Non-mammalian
    • 4.5.1. Non-mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Biosimilar Contract Manufacturing Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Biosimilar Contract Manufacturing Market: Service Movement Analysis
  • 5.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • 5.4. Recombinant Non-glycosylated Proteins
    • 5.4.1. Recombinant Non-glycosylated Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Recombinant Glycosylated Proteins
    • 5.5.1. Recombinant Glycosylated Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Biosimilar Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Biosimilar Contract Manufacturing Market: Therapeutic Area Movement Analysis
  • 6.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Blood Disorders
    • 6.5.1. Blood Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Growth Hormonal Deficiency
    • 6.6.1. Growth Hormonal Deficiency Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Chronic & Autoimmune Disorders
    • 6.7.1. Chronic & Autoimmune Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Rheumatoid Arthritis
    • 6.8.1. Rheumatoid Arthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Biosimilar Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Biosimilar Contract Manufacturing Market: Regional Movement Analysis
  • 7.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
  • 7.4. North America
    • 7.4.1. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East & Africa
    • 7.8.1. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.6. Oman
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Framework
      • 7.8.6.4. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.7. Qatar
      • 7.8.7.1. Key Country Dynamics
      • 7.8.7.2. Competitive Scenario
      • 7.8.7.3. Regulatory Framework
      • 7.8.7.4. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Assessment Analysis, 2024 (Company Heat Map Analysis)
  • 8.3. Key Company Profiles
    • 8.3.1. Boehringer Ingelheim GmbH
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Lonza
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Rentschler Biopharma SE
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. AGC Biologics
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. ProBioGen
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. FUJIFILM Diosynth Biotechnologies
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Toyobo Co. Ltd.
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Samsung Biologics
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Thermo Fisher Scientific, Inc.
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Binex Co., Ltd.
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. WuXi Biologics
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. AbbVie, Inc.
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. ADMA Biologics, Inc.
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Product Benchmarking
      • 8.3.13.4. Strategic Initiatives
    • 8.3.14. Catalent, Inc
      • 8.3.14.1. Company Overview
      • 8.3.14.2. Financial Performance
      • 8.3.14.3. Product Benchmarking
      • 8.3.14.4. Strategic Initiatives
    • 8.3.15. Cambrex Corporation
      • 8.3.15.1. Company Overview
      • 8.3.15.2. Financial Performance
      • 8.3.15.3. Product Benchmarking
      • 8.3.15.4. Strategic Initiatives
    • 8.3.16. Pfizer Inc.
      • 8.3.16.1. Company Overview
      • 8.3.16.2. Financial Performance
      • 8.3.16.3. Product Benchmarking
      • 8.3.16.4. Strategic Initiatives
    • 8.3.17. Siegfried Holding AG
      • 8.3.17.1. Company Overview
      • 8.3.17.2. Financial Performance
      • 8.3.17.3. Product Benchmarking
      • 8.3.17.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 4. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 5. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
  • Table 7. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 8. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 9. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 10. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 11. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 12. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 13. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 14. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 15. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 16. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 17. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 18. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 19. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 20. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 21. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 22. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 23. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 24. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 25. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 26. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 27. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 28. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 29. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 30. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 31. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 32. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 33. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 34. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 35. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 36. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 37. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 38. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 39. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 40. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 41. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 42. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 43. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 44. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 45. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 46. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 47. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 48. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 49. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 50. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 51. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 52. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 53. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 54. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 55. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 56. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 57. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 58. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 59. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 60. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 61. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 62. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 63. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 64. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 65. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 66. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 67. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 68. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 69. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 70. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 71. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 72. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 73. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 74. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 75. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 76. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 77. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 78. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 79. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 80. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 81. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 82. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 83. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 84. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 85. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 86. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 87. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 88. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 89. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 90. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 91. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 92. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 93. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 94. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 95. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 96. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 97. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 98. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 99. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 100. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 101. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Biosimilar contract manufacturing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market dynamics
  • Fig. 9 Market driver analysis (current & future impact)
  • Fig. 10 Market restraint analysis (current & future impact)
  • Fig. 11 Porter's five forces analysis
  • Fig. 12 PESTEL by SWOT analysis
  • Fig. 13 Biosimilar contract manufacturing source key takeaways (USD Million)
  • Fig. 14 Biosimilar contract manufacturing market: Source, market share 2024 & 2033
  • Fig. 15 Mammalian biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 Non-mammalian biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Biosimilar contract manufacturing therapeutic area key takeaways (USD Million)
  • Fig. 18 Biosimilar contract manufacturing market: therapeutic area, market share 2024 & 2033
  • Fig. 19 Oncology biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Blood disorders biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Growth hormonal deficiency biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Chronic & autoimmune disorders biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Rheumatoid arthritis biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Others biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Biosimilar contract manufacturing service key takeaways (USD Million)
  • Fig. 26 Biosimilar contract manufacturing market: service, market share 2024 & 2033
  • Fig. 27 Recombinant non-glycosylated proteins biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Recombinant glycosylated proteins biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Regional outlook, 2024 & 2033
  • Fig. 30 North America biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Canada biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Mexico biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Europe biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 UK biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Germany biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 France biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Italy biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Spain biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Denmark biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Sweden biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Norway biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Asia Pacific biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Japan biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 China biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 India biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Australia biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 South Korea biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Thailand biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Latin America biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Brazil biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Argentina biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 MEA biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 South Africa biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Saudi Arabia biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 UAE biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Kuwait biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Qatar biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Oman biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)